Better Buy: Bristol Myers Squibb vs. Merck

Pharmaceutical giant Merck (NYSE: MRK) has recently made headlines with its oral COVID-19 pill that was just approved in the U.K. Its competitor, Bristol Myers Squibb (NYSE: BMY), is looking to start reaping rewards from a late 2020 purchase of heart medication specialist MyoKardia.

Both are solid pharmaceuticals that can be the bedrock of your portfolio, offering both dividends and the potential for share price appreciation. But if you're considering investing in either Bristol Myers Squibb or Merck, here's how to decide which one is the better buy.

Image source: Getty Images.

Continue reading

Source Fool.com